Bio-rad Laboratories, INC Form 4 insider transactions

Eva Anette Engelhardt, EVP, President, CDG of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on July 25, 2026.

Bio-Rad Laboratories' EVP and CFO, Roop Kalyan Lakkaraju, acquired 1,078 shares of Class A common stock upon the vesting of restricted stock units.

Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, Inc., acquired shares through the vesting of restricted stock units and participation in the Employee Stock Purchase Plan.

Bio-Rad Laboratories Director Greg K. Hinckley acquired shares of Class A common stock upon the vesting of restricted stock units.

Bio-Rad Laboratories Director Melinda Litherland reported transactions involving the acquisition of Class A common stock upon the vesting of restricted stock units.

Bio-Rad Laboratories Director Jeffrey L. Edwards acquired shares of Class A common stock upon the vesting of restricted stock units.

Director Arnold A. Pinkston of Bio-Rad Laboratories acquired shares upon the vesting of restricted stock units.

Bio-Rad Laboratories EVP James Barry sold 699.873 shares of Class A Common Stock for approximately $306.18 per share on November 6, 2025, under a pre-arranged 10b5-1 plan.

Bio-Rad Laboratories' President & COO, Jonathan P. DiVincenzo, acquired shares through RSU vesting and sold a portion for tax obligations.

Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, reported the vesting of 1,044 restricted stock units and the subsequent sale of 335 shares for tax obligations.

Bio-Rad Laboratories' EVP of Global Supply Chain, Sedat Evran, reported the vesting of restricted stock units and related stock transactions.

Bio-Rad Laboratories' EVP and CFO, Roop Kalyan Lakkaraju, disclosed the vesting of restricted stock units, the acquisition of shares, and a subsequent sale for tax obligations, alongside a new RSU grant.

Colleen Corey, Bio-Rad's EVP of Global Human Resources, reported the vesting of 576 restricted stock units and the grant of 2,740 new units.

Bio-Rad Laboratories EVP, James Barry, reported the vesting of restricted stock units, a subsequent tax-related sale of Class A common stock, and a new grant of restricted stock units.

Bio-Rad Laboratories Director Allison Schwartz reported the acquisition of 914 new Restricted Stock Units and the vesting of 92 existing units, alongside related stock transactions.

Bio-Rad Laboratories' President and COO, Jonathan P. DiVincenzo, was granted 6,850 restricted stock units vesting over four years.

Bio-Rad Laboratories EVP, President, CDG Eva Anette Engelhardt reported the vesting of restricted stock units and related stock transactions.

Bio-Rad Laboratories' EVP, General Counsel & Secretary, Courtney C. Enloe, reported the vesting of restricted stock units and a subsequent tax-related sale of common stock.

Bio-Rad Laboratories' Chairman and CEO, Norman Schwartz, reported the vesting of restricted stock units and related share transactions.

Bio-Rad Laboratories' EVP of Global Commercial Operations, Rajat Mehta, received a grant of 7,307 restricted stock units.

Bio-Rad Laboratories Director Allison Schwartz reported the acquisition of 147 Class A common shares through RSU vesting and the disposition of 55 shares for tax purposes.

Bio-Rad Laboratories EVP James Barry reported the vesting of 602 restricted stock units and the subsequent disposition of 217 shares for tax purposes.

Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, reported the vesting of restricted stock units and subsequent share transactions.

Bio-Rad Laboratories' Chairman and CEO, Norman Schwartz, reported the scheduled vesting of restricted stock units and a subsequent tax-related share disposition.

Bio-Rad Laboratories EVP Eva Anette Engelhardt reported the acquisition of 245 shares of Class A common stock from restricted stock unit vesting and the disposition of 88 shares for tax purposes.

Roop Kalyan Lakkaraju, CFO of Bio-Rad Laboratories, reports the vesting of restricted stock units and a disposition of shares to cover tax obligations.

Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, reports acquisition and disposal of Bio-Rad A Common Stock due to vesting of restricted stock units and tax withholding.

Director Arnold A. Pinkston acquired 308 shares of Bio-Rad Laboratories Class A common stock through the vesting of restricted stock units on April 22, 2025.

Director Melinda Litherland Pei reports acquisition of Bio-Rad Laboratories Class A common stock through vesting of restricted stock units.

Gregory K. Hinckley, a director at Bio-Rad Laboratories, acquired 308 shares of Class A common stock through the vesting of restricted stock units on April 22, 2025.